Beam Therapeutics Inc.
BEAM
$31.58
-$0.17-0.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 157.97% | 120.01% | -84.07% | -82.90% | -82.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 157.97% | 120.01% | -84.07% | -82.90% | -82.38% |
| Cost of Revenue | 7.83% | -11.16% | -19.08% | -23.98% | -29.36% |
| Gross Profit | 32.80% | 38.56% | -382.76% | -325.66% | -281.07% |
| SG&A Expenses | 6.71% | 2.06% | -12.63% | -12.03% | -6.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.36% | 9.26% | -1.94% | -5.73% | -8.90% |
| Operating Income | 13.72% | 7.67% | -155.26% | -141.81% | -137.07% |
| Income Before Tax | 83.17% | 79.01% | -190.96% | -180.81% | -189.69% |
| Income Tax Expenses | -- | -- | -100.00% | -100.00% | -97.14% |
| Earnings from Continuing Operations | 83.17% | 79.02% | -188.11% | -178.05% | -186.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.17% | 79.02% | -188.11% | -178.05% | -186.79% |
| EBIT | 13.72% | 7.67% | -155.26% | -141.81% | -137.07% |
| EBITDA | 14.55% | 8.19% | -176.20% | -160.31% | -154.02% |
| EPS Basic | 86.08% | 79.06% | -157.09% | -155.03% | -164.15% |
| Normalized Basic EPS | 84.26% | 77.59% | -183.92% | -183.18% | -156.83% |
| EPS Diluted | 85.07% | 78.05% | -151.03% | -149.17% | -158.00% |
| Normalized Diluted EPS | 83.21% | 76.52% | -176.99% | -176.28% | -151.13% |
| Average Basic Shares Outstanding | 22.41% | 20.10% | 14.69% | 9.67% | 5.54% |
| Average Diluted Shares Outstanding | 23.02% | 20.72% | 14.05% | 9.05% | 4.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |